Join us for an on-demand webcast reviewing a dermatologic perspective on diagnosis, risk stratification, therapeutic selection, and coordinated care. After viewing this webcast, you'll be able to claim your complimentary CME/CE credits! Watch now: https://okt.to/wSvNPy
Dermatology Week’s Post
More Relevant Posts
-
New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gGFFDQaj
-
-
Business Development Director at Fortrea (formerly Covance, Labcorp). Supporting clinical development Phase I-IV for biotech companies
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gTg2T2rj
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/e5fPTiC3
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/eg3XEfCq
-
-
Strategic Transformation | 19 Patents | PSPO™ | PSM™ | LSSWB | LSSYB | LPLG | Microsoft Power BI Certified | Program And Project Management | Vendor Management | Operational Excellence| Data Analytics
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/dczMqHxG
-
-
Explore the expert discussion on navigating plaque psoriasis treatment. Mark Lebwohl, MD, and Saakshi Khattri, MD, provide insights into key therapeutic approvals from 2023 and address the unique challenges faced by patients with skin of color. Watch here: https://ow.ly/W8K050RamNS
-
-
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gCrkhD8S
-
-
Passionate Life Sciences Leader | Fast-Tracking Treatments for Patients | Making a Positive Difference ❤️ | HBA Ambassador Champion | WEN (Women Empowerment Network) India Co-Lead
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/grsPew4S
-
